Effect of monomer structure of anionic surfactant on voltammetric signals of an anticancer drug: rapid, simple, and sens
- PDF / 479,485 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 44 Downloads / 194 Views
RESEARCH PAPER
Effect of monomer structure of anionic surfactant on voltammetric signals of an anticancer drug: rapid, simple, and sensitive electroanalysis of nilotinib in biological samples Ceren Elif Sener 1 & Burcu Dogan Topal 1
&
Sibel A. Ozkan 1
Received: 26 May 2020 / Revised: 6 August 2020 / Accepted: 2 September 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract A rapid, simple, and highly sensitive electroanalytical method was developed for the first time for the detection of ultra-trace amounts of nilotinib in sodium lauryl sulphate media. The electrochemical behavior of nilotinib was investigated on a glassy carbon electrode in the absence and presence of sodium lauryl sulphate media by cyclic voltammetry and adsorptive stripping voltammetric methods. The cyclic voltammograms proved that the electrochemical behavior of nilotinib showed irreversible and diffusion–adsorption-controlled oxidation processes in 0.1 M H2SO4. The effect of surfactant concentration on the first and second peaks of nilotinib was examined. Depending on whether the surfactants had a monomer or monolayer hemimicelle structure, they were attracted to amine moieties at related points in the nilotinib structure through the electrostatic interaction. The sensitivity of the method was markedly enhanced in the presence of surfactants using adsorptive stripping square-wave voltammetry. Under optimum conditions, nilotinib was determined in a concentration range of 2.0 × 10−8 to 2.0 × 10−6 mol L−1, with a limit of detection of 6.33 × 10−9 mol L−1 in 0.1 M H2SO4 containing 2.0 × 10−7 mol L−1 sodium lauryl sulphate. The proposed method can be applied for the sensitive determination of nilotinib in biological samples. Keywords Nilotinib . Voltammetry . Determination . Sodium lauryl sulphate . Validation
Introduction Nilotinib (NLT) (Scheme 1), a selective tyrosine kinase inhibitor targeting breakpoint cluster region-Abelson murine leukemia (Bcr-Abl), with an IC50 value of 2.5 × 10−8 M, can be used in the treatment of patients with chronic myelogenous leukemia in cases of imatinib failure [1, 2]. The autophosphorylation and proliferation of 33 Bcr-Abl mutants was found to be inhibited by NLT in a concentration range of 20–800 nM (IC50 values). It was estimated that the large majority of BcrAbl mutants would be inhibited by NLT at therapeutic plasma Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00216-020-02934-9) contains supplementary material, which is available to authorized users. * Burcu Dogan Topal [email protected] * Sibel A. Ozkan [email protected] 1
Faculty of Pharmacy, Department of Analytical Chemistry, Ankara University, Tandogan, 06100 Ankara, Turkey
levels based on a clinical Cmax value of 4.3 × 10−6 M [2]. Unchanged NLT was found to be the predominant component in plasma, constituting 87.5 ± 9.2% of the total NLT [2]. Therapeutic drug monitoring of NLT is an important tool for treatment administration in patients with chronic myelogenous
Data Loading...
